Compare · AARD vs NVO
AARD vs NVO
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1358.0x AARD ($158.7M).
- Over the past year, AARD is down 25.1% and NVO is down 12.1% - NVO leads by 13.0 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for AARD).
- NVO has more recent analyst coverage (25 ratings vs 16 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $158.7M
- $215.46B
- 1M return
- +9.05%
- -2.08%
- 1Y return
- -25.08%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 8
- 9
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AARD
- SEC Form 4 filed by Director Chi Jeffrey
- SEC Form 4 filed by Director Graf Susan E
- SEC Form 4 filed by Director Baynes Roy D.
- SEC Form 4 filed by Director Tong Victor Edward Jr
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form DEF 14A filed by Aardvark Therapeutics Inc.
- SEC Form PRE 14A filed by Aardvark Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S